Gilead Reports Results of Remdesivir in P-III SIMPLE Studies for Patients with Severe COVID-19

Shots:

• The first SIMPLE study involves assessing of Remdesivir (5/10days dosing regimen, 200mg on the first day, followed by 100 mg each day until day 5 or 10, IV) + SOC in 397 patients in a ratio (1:1) with severe manifestations of COVID-19. An expansion study will enroll ~5600 patients including patients on mechanical ventilation
• The second SIMPLE study involves assessing Remdesivir (5/10days dosing regimen, IV) vs SOC in patients with moderate manifestations of COVID-19 with expected results from the first 600 patients at the end of May
• The study demonstrated that patients receiving remdesivir (10days) achieved similar improvement in clinical status compared with those taking a 5days regimen. Patients achieving clinical recovery @14day (64.5%/53.8%), time to clinical improvement for 50% patients (10days in the 5day treatment group and 11 days in the 10day treatment group)

Click here to­ read full press release/ article | Ref: Gilead | Image: Pink Sheet

Related News: Gilead Reports the Initiation of Two P-III Studies of Remdesivir to Treat COVID-19